Nutrasource rebrands its clinical trials site in Canada to focus on both nutraceutical and pharmaceutical studies
The focus of the newly named Apex Trials site ranges from Phase I pharmacokinetic studies to Phase IV studies for pharmaceuticals and nutraceuticals.
Photo © iStockphoto.com
Contract research organization Nutrasource (Guelph, ON, Canada) has rebranded its clinical trials site in Southwestern Ontario in Canada with the new name Apex Trials. This site focuses on Phase I pharmacokinetic studies to Phase IV studies for pharmaceuticals and nutraceuticals.
The Apex Trials clinical trials site focuses on nutraceutical and pharmaceutical studies for cardiovascular disease, hypertension, dyslipidemia, diabetes, irritable bowel syndrome, and weight management. The 17,000-sq-ft site includes more than 20 site staff, including nurse practitioners and clinical research coordinators.
Katie Keene, the clinic’s supervisor, said in a press release, “This latest change is our biggest and best yet as it will allow us to expand our focus beyond food and natural health product trials to include pharmaceutical trials, further growing our site’s portfolio of offerings.”
FDA revokes authorization to use Red No. 3 as a color additive in food or drugs
January 15th 2025FDA contends that the color additive is safe for humans but is legally obligated by the Delaney Clause of the FD&C act to revoke authorization as research shows the Red No. 3 induces cancer in rats.
